Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83035 | 0.69 | HSD11B1 (0.51) | HSD11B1ALOX5APMEN1KMT2AMAOA | |
| SCHEMBL87608 | 0.69 | HSD11B1 (0.55) | HSD11B1ALOX5APMEN1KMT2AMAOA | |
| SCHEMBL11026770 | 0.68 | SCN5A (0.44) | HSD11B1MEN1KMT2A | |
| SCHEMBL26436535 | 0.63 | GRIN1 (0.67) | SIGMAR1PRCPMEN1KMT2A | |
| SCHEMBL13216349 | 0.62 | HSD11B1 (1.00) | HSD11B1MEN1KMT2A | |
| SCHEMBL9631996 | 0.61 | MAOB (0.39) | HSD11B1MAOAMAOB | |
| SCHEMBL11111151 | 0.61 | HSD11B1 (0.35) | HSD11B1KMT2AMAOAMAOB | |
| SCHEMBL13216929 | 0.60 | HSD11B1 (0.68) | HSD11B1MEN1KMT2A | |
| SCHEMBL539376 | 0.60 | HSD11B1 (0.36) | HSD11B1MAOAMAOB | |
| SCHEMBL23595712 | 0.60 | SLC6A3 (0.61) | SIGMAR1PRCPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703799-B2 | Non-competitive NMDA receptor antagonists | ADEJARE ADEBOYE (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120129889-A1 | Non-competitive NMDA receptor antagonists | ADEJARE ADEBOYE (US) | 2012-05-24 | — | — | US | disclosed |
| US-8129414-B2 | Non-competitive NMDA receptor antagonists | Adejare, Adeboye (US) | 2012-03-06 | — | — | US | disclosed |
| US-20080039498-A1 | Non-competitive NMDA receptor antagonists | ADEJARE ADEBOYE | 2008-02-14 | — | — | US | disclosed |
| WO-2007149508-A2 | NON-COMPETITIVE NMDA RECEPTOR ANTAGONISTS | THE UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039498-A1 | Non-competitive NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2A | HSD11B1 4199/4885SIGMAR1 25/4885ALOX5AP 1234/4885 |
| US-20120129889-A1 | Non-competitive NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2A | HSD11B1 4199/4885SIGMAR1 25/4885ALOX5AP 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.